Pharma Exclusives Pressreleases
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
Wednesday, April 23, 2025Cybin Inc a clinicalstage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative nextgeneration treatment options today announced additional strategic partnership agreements
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
Monday, April 21, 2025Cybin Inc a clinicalstage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative nextgeneration treatment options today announced a strategic partnership
Thermo Fisher Scientific Opens Advanced Therapies Collaboration Center in Greater San Diego to Help Accelerate Cell Therapy Development
Thursday, April 17, 2025Thermo Fisher Scientific Inc the world leader in serving science today announced the grand opening of its Advanced Therapies Collaboration Center ATxCC in Carlsbad Calif This advanced facility is designed to accelerate the development
Aptar Announces Clinical Validation Study to Accelerate US FDA Approval of SmartTrack™ In-Vitro-in-Silico Platform for Pressurized Metered-Dose Inhalers
Wednesday, April 16, 2025AptarGroup Inc a global leader in drug and consumer product dosing dispensing and protection technologies today announces the commencement of a clinical study to validate its proprietary SmartTrack platform
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
Tuesday, April 15, 2025Bristol Myers Squibbtoday announced the Phase ODYSSEYHCM trial evaluating Camzyos mavacamten for the treatment of adult patients with symptomatic New York Heart Association NYHA class IIIII nonobstructive hypertrophic cardiomyopathy nHCM did not mee...
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
Thursday, April 10, 2025Inozyme Pharma Inca clinicalstage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function today announced the publication of a paper titled Phenotypic characterization of ENPP d...
Tonix Pharmaceuticals to Work with Makana Therapeutics on Preclinical and Clinical Xenotransplantation Studies Using TNX-1500 and Genetically Engineered Organs
Wednesday, April 09, 2025Tonix Pharmaceuticals Holding Corpa fullyintegrated biopharmaceutical company with marketed products and a pipeline of development candidates and Makana Therapeutics Inc Makana a global leader in the field of xenotransplantation today announced a col...
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis
Tuesday, April 08, 2025AbbVietoday announced that the European Commission EC granted marketing authorization to RINVOQ upadacitinib mg once daily for the treatment of giant cell arteritis GCA in adult patients RINVOQ is the first and only oral JAK inhibitor approved in th...
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
Monday, April 07, 2025Teva Pharmaceuticals a US affiliate of Teva Pharmaceutical Industries Ltdannounced today that the US Food and Drug Administration FDA has accepted its supplemental Biologics License Application sBLA for AJOVY fremanezumabvfrm to expand
Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
Tuesday, April 01, 2025Moderna Inctoday announced that the Australian Therapeutic Goods Administration TGA has granted approval for mRESVIA mRNA an mRNA respiratory syncytial virus RSV vaccine to prevent lower respiratory tract disease
